Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T101
- Development stage
- Phase 2
- Lead developer
- Tasly Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular
01
Overview
T101 is a therapeutic vaccine candidate developed by Tianjin Tasly Chuangshijie Biopharmaceutical for the treatment of chronic hepatitis B (CHB). It utilizes a replication-deficient adenovirus vector (typically Ad5) engineered to express hepatitis B virus (HBV) antigens. The primary goal of T101 is to break immune tolerance in CHB patients and stimulate a potent, virus-specific T-cell response to help achieve functional cure. It is often evaluated in clinical trials in combination with standard-of-care nucleos(t)ide analogues (NAs) to enhance the host's immune control over the virus.
- Other names
- Therapeutic Hepatitis B Adenovirus Injectionhepatitis B adenovirus injection
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on T101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T101.